Saturday, January 25, 2025

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.

from Top Health News -- ScienceDaily https://ift.tt/pKy7AWf
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

A protein older than blood circulation could transform cancer immunotherapy

A protein that evolved long before the human circulatory system may help unlock stronger cancer treatments. When C3 is produced inside tumor...